Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovation campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Deerfield Announces Financing Transaction with Flamel Technologies

February 07, 2013 08:31 AM  Eastern Daylight Time 

NEW YORK–(BUSINESS WIRE)–Deerfield Management Company announced that it had closed a transaction with Flamel Technologies (NASDAQ: FLML) and two of Flamel’s subsidiaries to provide $15 million. The objective of the financing is to enable Flamel to continue development programs and regulatory filings related to its internal pipeline of products.

Deerfield provided the $15 million in return for notes bearing 12.5% interest that amortize over a period from 18 months to 4 years. Deerfield also received a royalty of 1.75% of net sales of certain products being developed by Flamel’s U.S. subsidiary, Éclat Pharmaceuticals, and transaction fee. The structure was responsive to Flamel’s cash flow requirements and interest in avoiding equity dilution.

About Flamel Technologies

Flamel, headquartered in Lyon, France, focuses on developing specialty pharmaceutical products to address unmet medical needs through the application of its drug delivery technologies. The financing provides Flamel with additional resources to continue developing a pipeline of specialty pharmaceutical products and explore further expansion of applications for its drug delivery technology.

About Deerfield Management Company

Deerfield is committed to advancing healthcare through investment, information and philanthropy.

For more information about Deerfield, please visit www.deerfield.com

Contacts

Deerfield Management Company
Karen Arnone, 212-922-1349
[email protected]